HEALTH OF WOMAN. 2016.1(107):18–29; doi 10.15574/HW.2016.107.18 
 

Multitargeted approach to treatment of fibrocystic breast disease and breast cancer prevention 
 

Potapov V. A.

SІ «Dnipropetrovsk medical Academy Ministry of health of Ukraine» 
 

In the article the data on the genetic and molecular and epigenetic mechanisms of carcinogenesis, shows the evolution of phenotypic similarity benign hyperplastic processes of mammary glands and breast cancer (BC). With critical positions represented a modern strategy for the prevention and treatment of breast cancer, benign breast disease, conducted an analysis of a number of pharmacological efficacy of drugs for these purposes are disclosed benefits of targeted therapy with phytonutrients.

From the standpoint of evidence-based discussion about onkoprotection properties mediating most of the major pathogenetic links hyperproliferation and tumor growth in mammary glands, fitocomposition Epigalin Brest, active ingredients which are natural dopamine agonist – Vitex agnus–castus extract usual and the two most famous fitoprotection targeted 3,3-Diindolymethane and epigallocatechin-3-gallate, as well as the possibility of using Epigalin Brest as multitargeted therapy benign breast disease and prevention of carcinogenesis in women at risk for breast cancer.

It is concluded that Epigalin Brest is unique fitoresources as an additional component to the diet daily diet in order to maintain the normal state of function of cells and natural deterministic genetic mechanisms onkoprotection as in patients with benign breast disease, and in healthy women who want to make informed choices in relation to the safe the prevention of breast cancer, the risk of developing that over the life of each woman has. 
 

Key words: fibrocystic breast disease, therapy, prevention of breast cancer, fito composition Epigalin Brest. 
 

REFERENCES

1. Ashrafyan L A, Kiselev VI, Moigne EL 2009. Pathogenetic prevention of cancer of the reproductive organs. M, Publishing house of Dimitra Schedule Groups:176.

2. Baranov VS. 2009. Genetic passport – the basis of individual and predictive medicine. Ed. by V. Baranov. SPb, Publishing house N-L:528.

3. Burdina L M 2007. Dyshormonal hyperplasia of mammary glands – development features, differential diagnosis. Radiola. Practical. 3:44-61.

4. Uropathogen P N Verapamile NP, T TV. 2009. Of breast disease associated with genetic disorders. Women's health 5(41):204-212.

5. Vysotskaya I V 2009. Modern therapy of fibrocystic breast disease. Tumors of the female reproductive system 1-2:44-46.

6. Galitsky V A 2003. Carcinogenesis and mechanisms of intracellular signaling. Oncology 49;3:278-293.

7. Goryshina OG 2002. The role of prolactin in the Genesis of mastitis. Bulletin of new medical technologies 4:22-24.

8. Goryacheva L A, Pinhosevich EG 2006. Phytotherapy in diseases of the mammary glands. M:23.

9. Gromova O A, Rebrov V G 2005. Vitamins and carcinogenesis: myths and reality. Reprod. the health of children and adolescents 1:80-96.

10. Dedov I I, Melnichenko G. A., Romantsova T. I. 2004. Syndrome of hyperprolactinemia. M:304.

11. Zotov A. S., Belik EO 2005. Mastopathy and breast cancer. M, Medpress-inform:112.

12. Zulkarnaeva A. T. Khakimov R. H., LAPAN, E. I., Blagodetel I. L. 2008. Indinol-3-carbinol in the treatment of benign breast disease. Tumors of the female reproductive system 3:50-54.

13. Kiselev VI, Lyashenko A A 2008. Indinol regulator of proliferative processes in the organs of the reproductive system. M, JSC "Miraxpharma":48.

14. Kisilev, VI., Lyashenko AA 2005. Molecular mechanisms of regulation of hyperplastic processes. M, Publishing house of Dimitra Graph of Groups:348.

15. Kuligin, E. S. 2010. Epidemiological and molecular aspects of breast cancer. Practical. Oncology 11;4:203-216.

16. Letyagin V., Vysotskaya I V 2007. The treatment of diffuse fibrocystic breast disease. Tumors of the female reproductive system 2:47-49.

17. Mustafin K., Kuznetsov S. V. 2009. Dyshormonal diseases of the mammary gland. Clinical leadership. Under the editorship of Pinhosevich ER. M:126.

18. Nosov D. A. 2004. Targeted therapy of malignant tumors. Together against cancer. Spec. release:17-24.

19. Ovsyannikova T. V. 2006. Dyshormonal pathologies of the mammary glands – the eyes of a gynecologist. Benign breast disease 10:22-38.

20. Osinsky S. P., Gluzman D F, Cliff J. and others 2007. Molecular diagnosis of tumors. TO, DIA:246.

21. Pak DD, Usov FN, Fetisova Y Eand others 2013. Modern approaches to the treatment of patients with carcinoma in situ of the breast. Oncology 4:34-39.

22. Popov BV2010. Introduction into cell biology of stem cells. SPb:319.

23. Potapov, VA 2014. The role of epigenetic factors in tumor pathology of the uterus and breast cancer. S turbota Pro inku 7(55).

24. Prilepskaya VN, Tagiev T. T. 2008. Fibrocystic disease of the breast: potential non-hormonal therapy. Medline Express 5:10-17.

25. Prevention and diagnostics of dyshormonal breast diseases: a clinical Protocol (MOH Order of Ukraine № 676).

26. Radzinsky V. E. 2010. The breast and gynecological diseases. Under. ed. by VE Radzinsky. M:304.

27. Radzinsky V. E., And I. M. Ordiyants 2011. Premenstrual syndrome and benign dysplasia of breast cancer: realities and prospects. Women's health 1(57):71-75.

28. Breast cancer: unified clinical Protocol of primary, secondary (specialized), tertiary (highly specialized) medical care (order of MOH of Ukraine № 396).

29. Sergeeva NAnd., Dzeranova L K, Meskich E V, 2005. The involvement of prolactin in mammogenesis and carcinogenesis of the mammary gland. Obstetrics and gynecology 3:13-17.

30. Tagiyev T T 2004. Breast: non-hormonal methods of treatment. Gynecology 6;5:228-230.

31. Tarutinov VI 2009. Breast: cancer and premalignant diseases. To, in the "Book plus":479.

32. Tovstanovska VA, Sparrow-Vigovskaya V. N., Sakharov, I. A. 2010. A new word in non-hormonal therapy of fibrocystic breast disease. Women's health 1(47):64-66.

33. Filippov O. S. 2008. Benign breast disease. M, Medpress:112.

34. Chaika VK, Sergienko M Yu, L V Zelenogra 2009. Treatment of patients with dishormonal diseases of mammary glands from the position of endocrinological gynecology. ROS. journal of akush.-Hynek. 1:71-75.

35. Chesnokova N.P., badgers VU, Slabnov O.A. 2012. Breast cancer: the problems of pathogenesis. Fundamental research 4-1:146-151.

36. Yalkut S.I., Potebnya G.P. 2010. Biotherapy of tumors. To, in the "Book plus":472.

37. Auborn KJ, Fan S, Rosen EM et all. 2003, Jul. lndole-3-carbinol is a negative regulator of estrogen. J. Nutr. 133(7 Suppl):2470–2475.

38. Bradlow HI, Telang NT, Sepkovic D.W. et all. 1996, Sep. 2-hydroxyestrone, the ‘good’ estrogen. J Endocrinol. 150 Suppl:259–265.

39. Brandi G, Paiardini M, Cervasi B et all. 2003. A new indole-3-carbinol tetrameric derivative inhibits cyclin-dependent kinase 6 expression, and induces G1 cell cycle arrest in both estrogen-dependent and estrogen-independent breast cancer cell lines. Cancer Res. 63;14:4028–4036.

40. Brignall MS. 2001. Prevention and treatment of cancer with indole-3-carbinol. Altern. Med. Rev. 6:580–589.

41. Castillo E, Garibay M, Mirabent F. 2006. Effect of alfa dihydroergocriptine in patients with fibrocistiс breast disease. Gynecol. Obstet. Mex. 74:580–584.

42. Chen P, Yang CC, Chen YJ, Wang PH. 2003. Tamoxifen-induced endometrial cancer. Eur. J. Gynaecol. Oncol. 24(2):135–137.

43. Cover СМ, Hsieh SJ, Cram EJ. 1999. lndole-3-carbinol and tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells. Cancer Res. 59(6):1244–1251.

44. Daniele C, Thompson Coon J, Pittler MH, Ernst E. 2005. Vitex agnus castus: a systematic review of adverse events. Drug. Saf. 28:319–332. http://dx.doi.org/10.2165/00002018-200528040-00004; PMid:15783241

45. Gardner DG, Shoback D. 2010. Bazisnaya i klinicheskaya endokrinologiya. Per. s angl. M, Binom-Press: 464.

46. Fuller GM, Shields D. 2013. Molekulyarnaya biologiya kletki. Per. s angl. M, Binom-Press:256.

47. Firestone GL, Bjeldanes LF. 2003. lndole-3-carbinol and З-З’-diindolylmethane antiproliferative signaling pathways control cell-cycle gene transcription in human breast cancer cells by regulating promoter-Sp1 transcription factor interactions. J.Nutr. 133(7):2448–2455.

48. Freedman AN, Seminara D, Gail MH et al. 2005. Cancer risk prediction models: a workshop on development, evaluation, and application. J.Natl. Cancer Inst. 97:715–723. http://dx.doi.org/10.1093/jnci/dji128; PMid:15900041

49. Guray M, Sahin AA. 2006. Benign breast diseases: classification, diagnosis, and management. Oncologist. 11:435–449. http://dx.doi.org/10.1634/theoncologist.11-5-435; PMid:16720843

50. Jung YD, Ellis LM. 2001. Inhibition of tumour invasion and angiogenesis by epigallocatechin gallate (EGCG), a major component of green tea. Int.J.Exp.Pathol. 82(6):309–316.

51. Kastan MB, Bartek J. 2004. Cell-cycle checkpoints and cancer. Nature. 116:273–279.

52. KiIicdag ЕВ. 2004. Fructus agni casti and bromocriptine for treatinent of hyperprolactinemia and mastalgia. Intl.J.Gyn&Ob. 85:292–293.

53. Knudson AG. 2002. Cancer genetics. Am.J.Ved.Genet. 111:96–102. http://dx.doi.org/10.1002/ajmg.10320; PMid:12124744

54. Kumru AM, Tezcan SE. 2003. Fluoxetine Versus Vitex agnus castus extrakt in the treatment of premenstrual disorder. Hum.Psychopharmacol. 18(3):191–195. http://dx.doi.org/10.1002/hup.470; PMid:12672170

55. Liang YC, Lin-Shiau SY, Chen CF. 1999. Inhibition of cyclin-dependent kinases 2 and 4 activities as well as induction of Cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by epigallocatechin-3-gallate. Lin.J.Cell.Biochem. 75:1–12. http://dx.doi.org/10.1002/(SICI)1097-4644(19991001)75:1<1::AID-JCB1>3.3.CO;2-E; http://dx.doi.org/10.1002/(SICI)1097-4644(19991001)75:1<1::AID-JCB1>3.0.CO;2-N

56. Lewin B, Cassimeris L, Lingappa VR, Plopper G. 2011. Kletki. Per. s angl. M, BINOM. Laboratoriya znaniy: 951.

57. Lewin B. 2012. Geni. Per. s angl. M, BINOM. Laboratoriya znaniy: 896.

58. Massague J. 2004. G1 cell-cycle control and cancer. Nature 432:298–306. http://dx.doi.org/10.1038/nature03094; PMid:1554909

59. Martin GS. 2001. The hunting of the Src. Nat.Rev.Mol. Cell Biol. 2:467–475. http://dx.doi.org/10.1038/35073094; http://dx.doi.org/10.1128/MCB.21.2.467-475.2001; PMCid:PMC86601

60. Martinez-Arribas F, Nunez-Villar MJ, Luca AR et all. 2003. Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients. Anticancer Res. 23(1):565–568.

61. Miltenburg DM, Speights VO. 2008. Benign breast disease. Obstet.Gynecol.Clin.North Am. 35:285–300. http://dx.doi.org/10.1016/j.ogc.2008.03.008; PMid:18486842

62. Rabson A, Roitt IM, Delves PJ. 2006. Osnovi meditzinskoy immunologii. Per. s angl. M, Mir: 320.

63. Santen RJ, Mansel R. 2005. Benign breast disorders. N.Engl.J.Med. 353:275–285. http://dx.doi.org/10.1056/NEJMra035692; PMid:16034013

64. Sarkar FH, Rahman KM, Li Y. 2003. Bax translocation to mitochondria is an important event in inducing apoptotic cell death by indole-3-carbinol (I3C) treatment of breast cancer cells. J.Nutr. 133(7):2434–2439.

65. Wuttke W, Jarry H, Christoffel V. 2003. Chaste tree (Vitex agnus-castus) – pharmacology and clinical indications. Phytomed. 10:348–357. http://dx.doi.org/10.1078/094471103322004866; PMid:12809367

66. Yang CS, Landau JM, Huang MT, Newmark HL. 2001. Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu. Rev. Nutr. 21:381–406. http://dx.doi.org/10.1146/annurev.nutr.21.1.381; PMid:11375442